Esperion Therapeutics, Inc. (ESPR)
Market Cap | 357.13M |
Revenue (ttm) | 277.79M |
Net Income (ttm) | -98.50M |
Shares Out | 196.22M |
EPS (ttm) | -0.68 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 6,850,746 |
Open | 1.610 |
Previous Close | 1.610 |
Day's Range | 1.580 - 1.830 |
52-Week Range | 0.700 - 3.400 |
Beta | 1.00 |
Analysts | Buy |
Price Target | 8.17 (+348.9%) |
Earnings Date | Nov 5, 2024 |
About ESPR
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company’s products als... [Read more]
Financial Performance
In 2023, Esperion Therapeutics's revenue was $116.33 million, an increase of 54.14% compared to the previous year's $75.48 million. Losses were -$209.25 million, -10.45% less than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ESPR stock is "Buy." The 12-month stock price forecast is $8.17, which is an increase of 348.90% from the latest price.
News
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on September 23, 2024, the Company granted one new employee 3,500 restricted stock units (RSUs) under ...
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)
– New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More Than 65% of Medicare Insured Lives and More Than 92% of Commercially Insur...
Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
ANN ARBOR, Mich., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 26th Annual Global Investment Confer...
Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs
Meeting expectations with revenue growth, expense guidance, and sales execution. Potential overhang from financial engineering with complex deals, warrants, and generic litigants. Maintaining a buy ra...
Esperion Therapeutics: Strategically Positioned To Grow
Esperion is a pharmaceutical firm whose focus is to treat patients with high low-density lipoprotein cholesterol (LDL-C). I rate it a buy due to strategic initiatives and market potential driving sign...
Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript
Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
– Total Revenue Increased 186% Year-over-Year to $73.8 Million with U.S. Net Product Revenue of $28.3 Million, Representing 39% Growth –
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 7, 2024, the Company granted 18 new employees 66,800 restricted stock units (RSUs) under Espe...
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) –
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
– OMERS Life Sciences to Purchase Esperion's European Royalty on Bempedoic Acid Products for $304.7 Million with European Royalties Reverting to Esperion Once OMERS Receives 1.7 Times its Investment –
Esperion to Participate in Upcoming June Investor Conferences
ANN ARBOR, Mich., May 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, wh...
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
ANN ARBOR, Mich., May 20, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) and Otsuka Pharmaceutical Co., Ltd (Otsuka) announced today that the primary endpoint was achieved in the Phase 3 trial in Ja...
Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock
Esperion Therapeutics secured FDA approval for expanded labels of its flagship drugs and obtained a patent extension. Despite these successes, the stock trades with the weight of an abiding skepticism...
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
ANN ARBOR, Mich., May 14, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the U.S. Patent and Trademark Office (USPTO) issued a U.S. Patent Term Extension (PTE) certificate for b...
Esperion Therapeutics, Inc. (ESPR) Q1 2024 Earnings Call Transcript
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Conference Call May 7, 2024 8:00 AM ET Company Participants Tiffany Aldrich - Associate Director, Corporate Communications Sheldon Koenig - ...
Esperion Reports First Quarter 2024 Financial Results
– Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – – Q1 Retail Prescription Equivalents Grew 43% Y/Y ...
Esperion to Participate in Upcoming May Investor Conferences
ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May, ...
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
– Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to Placebo –
Esperion Therapeutics (ESPR) CEO on Cholesterol Lowering Medications
Esperion Therapeutics (ESPR) specializes in cholesterol lowering medications. President and CEO Sheldon Koenig joins Nicole Petallides to give an overview of the company.
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
ANN ARBOR, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced that Sheldon Koenig, President and CEO, will ring the Nasdaq Stock Market (Nasdaq) opening bell at 9:30 a.m...
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
ANN ARBOR, Mich., March 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 23rd Annual Needham Virtual Healthcare Conference. Sheldon Koenig, President and C...
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
ANN ARBOR, Mich., March 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the acceptance of three CLEAR ( C holesterol L owering via B e mpedoic acid, an A CL-Inhibiting R egimen) ...
U.S. FDA Approves Broad New Labels for Esperion's NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
ANN ARBOR, Mich.--(BUSINESS WIRE)--Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL® (bempedoic ac...
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
– New Labels Expand Treatable Population to ~70 Million Patients in U.S. – – First LDL-C Lowering Non-Statin Indicated for Primary Prevention Patients – – Approvals Based on Positive CLEAR Outcomes Da...
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
– Positive CHMP Opinions Are Based On The Analyses Of The Phase 3 Of The CLEAR (Cholesterol Lowering via Bempedoic Acid, an ATP Citrate Lyase (ACL)-Inhibiting Regimen) Outcomes Trial 1 –